Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced expanded medical policy coverage of its OVA1 test, following Blue Cross Blue Shield of Michigan's recent decision to include OVA1 in its medical policy guidelines.

Blue Cross Blue Shield of Michigan, the largest health plan in Michigan, covering 5.4 million members, joins several other Blue Cross Blue Shield plans that have adopted positive coverage for OVA1, including:

• Highmark Blue Cross Blue Shield, with more than 4 million members across Pennsylvania, Delaware and West Virginia;
• Blue Cross Blue Shield of Louisiana, which covers more than 1.4 million members;
• Blue Cross Blue Shield of Alabama, with approximately 3 million members; and
• Blue Cross Blue Shield of Arkansas, with nearly 400,000 members

"We are encouraged to see the increase in adoption of OVA1 by insurance providers," said Holly Bauzon, Vice President of Managed Markets for Vermillion. "As our medical providers continue to demonstrate the value of OVA1 through a growing network of referrals, we are confident patient access to our test through the health plans will grow as well. We are excited about more health plans recognizing how OVA1 meets a clear clinical need in ovarian cancer diagnostics."